Skip to content
Pretomanid, Dovprela (previously pretomanid fgk)(pretomanid)
Dovprela (pretomanid) is a small molecule pharmaceutical. Pretomanid was first approved as Pretomanid on 2019-08-14. It is used to treat extensively drug-resistant tuberculosis in the USA. It has been approved in Europe to treat multidrug-resistant tuberculosis.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pretomanid
Tradename
Company
Number
Date
Products
PRETOMANIDMylanN-212862 RX2019-08-14
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
pretomanidNew Drug Application2020-04-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
extensively drug-resistant tuberculosisD054908
Agency Specific
FDA
EMA
Expiration
Code
PRETOMANID, PRETOMANID, MYLAN IRELAND LTD
2029-08-14GAIN
2026-08-14ODE-253
2024-08-14NCE
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J04: Antimycobacterials
J04A: Drugs for treatment of tuberculosis
J04AK: Other drugs for treatment of tuberculosis in atc
J04AK08: Pretomanid
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
TuberculosisD014376EFO_0000774A15-A19944116
Pulmonary tuberculosisD014397EFO_1000049A1510612
Multidrug-resistant tuberculosisD018088EFO_00073811668
Extensively drug-resistant tuberculosisD054908344
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N1911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePRETOMANID
INNpretomanid
Description
Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth.
Classification
Small molecule
Drug classmycolic acid inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(OC(F)(F)F)cc1)C2
Identifiers
PDB
CAS-ID187235-37-6
RxCUI
ChEMBL IDCHEMBL227875
ChEBI ID
PubChem CID456199
DrugBankDB05154
UNII ID2XOI31YC4N (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,075 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
144,929 adverse events reported
View more details